Growth Dynamics on Hemophilia Drugs Market 2018-2025| Key Players: Grifols, CSL

Posted by Rushikesh Pise on December 3rd, 2019

The Global Hemophilia Treatment Drugs Market covered the value of US$ 9875.4 Mn in the year 2017 and is anticipated to reach US$ 15830.3 Mn by 2025. Furthermore, the global market for hemodialysis is expected to report a CAGR of 6.0% during the forecast period. The above information was published in a report, titled “Hemophilia Drugs Market Size, Share and Global Trend by Disease Indication (Hemophilia A, B & C), Therapy Type (Recombinant Therapy, Plasma therapy & Others), Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography Forecast till 2025.”

Browse Complete Report Details:

https://www.fortunebusinessinsights.com/industry-reports/hemophilia-drugs-market-100068

List of the Main Key Players Covered in Hemophilia Treatment Drugs Market Report

•          Grifols SA
•          CSL Behring
•          Octapharma
•          Pfizer
•          Bioverativ Inc.
•          FERRING LÄKEMEDEL AB
•          Aptevo Therapeutics
•          Takeda Pharmaceutical Company Limited
•          Roche Ltd
•          Novo Nordisk

The Asia Pacific to Grow at a Rapid Pace with Rising Number of Hemophilia Patients

North America is projected to emerge dominant in the global hemophilia drugs market during the forecast period. This is mainly ascribable to the rising prevalence of hemophilia A and B, especially in countries such as Canada and the U.S. Moreover, in 2017, North America market for hemophilia drugs covered a value of US$ 3,684.7 Mn. Trailing North America, Europe is the second-leading region in the global Hemophilia Treatment Drugs Market.

The growth in this region is attributable to the rising healthcare budgets by governments and initiatives by governments to promote hemophilia drugs treatment. On the other hand, the hemophilia drugs market in the Asia Pacific is likely to expand at a higher CAGR between 2017 and 2025 on account of the rising number of patients suffering from hemophilia especially in countries such as China and India.

The rising prevalence of severe diseases is one of the major concerns in the healthcare industry. Among these disorders, patients with hemophilia suffer from an abnormal blood loss and this weakens their blood clotting process. Companies are introducing novel hemophilia drugs and therapies to fulfill the unmet needs of patients and maintain their quality of life.

A lead analyst at Fortune Business Insights said, “Companies are building expansion strategies to develop new hemophilia drugs so as to offer a better diagnosis.” Among disease indications, hemophilia A is projected to exhibit strong growth in the coming years. In addition to this, this segment covered a share of 85% in the global hemophilia drugs market in 2017.

This is mainly attributable to the rising pool patients suffering from hemophilia across the world. Also, rising initiatives at developing and commercializing new products for the effective treatment of hemophilia is driving this segment’s growth. Following hemophilia, A, hemophilia B drugs are also expected to grow at a considerable rate in the years to come.